vs
CareDx, Inc.（CDNA）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Resolute Holdings Management, Inc.的季度营收约是CareDx, Inc.的1.0倍（$117.7M vs $117.7M），CareDx, Inc.净利率更高（2.4% vs -1.5%，领先3.8%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $514.0K）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
CDNA vs RHLD — 直观对比
营收规模更大
RHLD
是对方的1.0倍
$117.7M
净利率更高
CDNA
高出3.8%
-1.5%
自由现金流更多
RHLD
多$188.7M
$514.0K
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $117.7M |
| 净利润 | $2.8M | $-1.7M |
| 毛利率 | — | 55.7% |
| 营业利润率 | 1.0% | 30.2% |
| 净利率 | 2.4% | -1.5% |
| 营收同比 | 39.0% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.05 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARHLD
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $117.7M | ||
| Q3 25 | $100.1M | $120.9M | ||
| Q2 25 | $86.7M | $119.6M | ||
| Q1 25 | $84.7M | $103.9M | ||
| Q4 24 | $86.6M | — | ||
| Q3 24 | $82.9M | — | ||
| Q2 24 | $92.3M | — |
净利润CDNARHLD
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-1.7M | ||
| Q3 25 | $1.7M | $-231.0K | ||
| Q2 25 | $-8.6M | $-611.0K | ||
| Q1 25 | $-10.4M | $-3.4M | ||
| Q4 24 | $87.7M | — | ||
| Q3 24 | $-10.6M | — | ||
| Q2 24 | $-4.6M | — |
毛利率CDNARHLD
| Q1 26 | — | — | ||
| Q4 25 | — | 55.7% | ||
| Q3 25 | — | 59.0% | ||
| Q2 25 | — | 57.5% | ||
| Q1 25 | — | 52.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率CDNARHLD
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 30.2% | ||
| Q3 25 | -0.2% | 34.3% | ||
| Q2 25 | -12.8% | 34.0% | ||
| Q1 25 | -15.8% | 24.7% | ||
| Q4 24 | 97.5% | — | ||
| Q3 24 | -16.6% | — | ||
| Q2 24 | -7.9% | — |
净利率CDNARHLD
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -1.5% | ||
| Q3 25 | 1.7% | -0.2% | ||
| Q2 25 | -9.9% | -0.5% | ||
| Q1 25 | -12.2% | -3.2% | ||
| Q4 24 | 101.3% | — | ||
| Q3 24 | -12.8% | — | ||
| Q2 24 | -5.0% | — |
每股收益（稀释后）CDNARHLD
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $-0.20 | ||
| Q3 25 | $0.03 | $-0.03 | ||
| Q2 25 | $-0.16 | $-0.07 | ||
| Q1 25 | $-0.19 | $-0.39 | ||
| Q4 24 | $1.60 | — | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $205.5M |
| 总债务越低越好 | — | $169.8M |
| 股东权益账面价值 | — | $6.5M |
| 总资产 | $411.1M | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资CDNARHLD
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $205.5M | ||
| Q3 25 | $194.2M | $148.0M | ||
| Q2 25 | $186.3M | $99.9M | ||
| Q1 25 | $230.9M | $71.0M | ||
| Q4 24 | $260.7M | — | ||
| Q3 24 | $240.9M | — | ||
| Q2 24 | $228.9M | — |
总债务CDNARHLD
| Q1 26 | — | — | ||
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNARHLD
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $6.5M | ||
| Q3 25 | $311.1M | $10.8M | ||
| Q2 25 | $327.4M | $9.6M | ||
| Q1 25 | $379.3M | $8.9M | ||
| Q4 24 | $378.4M | — | ||
| Q3 24 | $273.2M | — | ||
| Q2 24 | $264.7M | — |
总资产CDNARHLD
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $333.4M | ||
| Q3 25 | $432.3M | $293.2M | ||
| Q2 25 | $444.3M | $253.3M | ||
| Q1 25 | $489.6M | $214.3M | ||
| Q4 24 | $491.1M | — | ||
| Q3 24 | $477.0M | — | ||
| Q2 24 | $466.8M | — |
负债/权益比CDNARHLD
| Q1 26 | — | — | ||
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $189.2M |
| 自由现金流率自由现金流/营收 | 0.4% | 160.8% |
| 资本支出强度资本支出/营收 | — | 5.8% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $313.2M |
8季度趋势，按日历期对齐
经营现金流CDNARHLD
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $196.1M | ||
| Q3 25 | $37.4M | $59.6M | ||
| Q2 25 | $9.9M | $48.9M | ||
| Q1 25 | $-26.6M | $18.4M | ||
| Q4 24 | $21.9M | — | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $18.9M | — |
自由现金流CDNARHLD
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $189.2M | ||
| Q3 25 | — | $58.6M | ||
| Q2 25 | — | $47.5M | ||
| Q1 25 | — | $17.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
自由现金流率CDNARHLD
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 160.8% | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 39.7% | ||
| Q1 25 | — | 17.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
资本支出强度CDNARHLD
| Q1 26 | — | — | ||
| Q4 25 | — | 5.8% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金转化率CDNARHLD
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RHLD
暂无分部数据
